IMMAGINA BioTechnology s.r.l (The Ribosome Company) is a company operating in the MedTech sector of Genomics, Proteomics and Enabling Technology, that is incubated in the Laboratory for Biomolecular Sequence and Structure Analysis for Health in Trento (Italy). Our mission is to deliver high-quality solutions to assess translational control of gene expression and translatome-associated biomarkers. IMMAGINA was founded in 2014, when the founders started to develop RiboLace, the only technology that enables the capture of active ribosomes. RiboLace is on the market from November 2018. Starting from 2016, thanks to the levering investments from private investors (of whom the most relevant one is BAN/TN, TBA network and the Herman Hauser Investment) and the recruitment of new experienced scientists, two new technologies for translatome analysis (AHARIBO and circAID-p-seq) were developed and finally launched on the market at the end of 2019. IMMAGINA offers a platform of products with the potential to accelerate the path toward the discovery of novel therapeutic strategies.